Skip to main content
Pay Bill Portals

ProActive

  1. Proactive Brochure Image ATC 2023 ProActive Study Interim Data Summary

    Presented at ATC 2023, the ProActive Study interim data solidifies Prospera as a non-invasive surveillance tool

  2. Abstract 2 Image ProActive Study: Donor-derived cfDNA fraction levels in stable kidney transplant recipients in the first year after transplant

    Presented at ATC 2023, interim ProActive Study data demonstrated that Prospera dd-cfDNA levels were persistently below 1% in 86.9% of clinically stable patients

  3. Abstract 3 Image ProActive Study: Elevations from baseline dd-cfDNA fraction are associated with acute allograft rejection in kidney transplant recipients

    Presented at ATC 2023, interim ProActive Study data demonstrated that Prospera dd-cfDNA fraction from baseline results in kidney transplant recipients who experienced rejection (60x median elevation), clearly setting them apart from those who did not (1.3x median elevation)

  4. Bromberg PowerPoint from ATC Image ProActive Study: Prospera Predicted ABMR up to 4 months, TCMR up to 2 months before BPAR

    Presented at ATC 2023, Prospera Kidney predicted antibody-mediated rejection (ABMR) up to four months and T cell-mediated rejection (TCMR) up to two months in advance of biopsy-proven rejection

  5. Bromberg Video Image ProActive Study: Dr Bromberg presents new data showing Prospera predicted ABMR up to 4 months, TCMR up to 2 months before BPAR

    Listen to Dr. Jonathan Bromberg, ProActive Study's lead Investigator, discuss how Prospera™ accurately predicted ABMR and TCMR before biopsy-proven rejection, up to 4 months and 2 months in.

  6. Qazi Fireside Chat Video- Natera Library Image Inside the ProActive Study On Demand Series: Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update

    Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update. In this episode, we discuss his:
    -journey to implement cfDNA as a transplant surveillance tool
    -considerations around high risk patients versus high risk situations for protocolized cfDNA care
    -Approach to use cfDNA given the recent CMS article

  7. Qazi Fireside Chat Audio Image Inside the ProActive Study On Demand Series: Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update - Audio Only

    Episode 1 - How Dr. Yasir Qazi embraced cfDNA surveillance, an unaffected approach due to the recent CMS update. In this episode, we discuss his:
    -journey to implement cfDNA as a transplant surveillance tool
    -considerations around high risk patients versus high risk situations for protocolized cfDNA care
    -Approach to use cfDNA given the recent CMS article

  8. Dr. Matthew Cooper Inside the ProActive Study On Demand Series: Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement - Audio Only

    Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement. In this episode, we discuss his:
    -Clinical experience using Prospera, supported by the interim ProActive Study data
    -Perspective on the recent ASTS guidelines suggesting cfDNA for surveillance use
    -Advice on how interested clinicians can implement cfDNA for surveillance

  9. Dr. Matthew Cooper Inside the ProActive Study On Demand Series: Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement

    Episode 2 - How Dr. Matthew Cooper sees cfDNA value to replace protocol biopsies, in-line with the ASTS Position Statement. In this episode, we discuss his:
    -Clinical experience using Prospera, supported by the interim ProActive Study data
    -Perspective on the recent ASTS guidelines suggesting cfDNA for surveillance use
    -Advice on how interested clinicians can implement cfDNA for surveillance

  10. Dr. Millie Samaniego-Picota Inside the ProActive Study On Demand Series: Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use

    Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use. In this episode, we discuss her:
    -experience expanding protocolized use on non-study patients
    -patients belief in the value of serial Prospera testing through the right education
    -message to colleagues looking to begin using cfDNA/p>

  11. Dr. Millie Samaniego-Picota Inside the ProActive Study On Demand Series: Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use Audio - Audio Only

    Episode 4 - How Dr. Milagros Samaniego-Picota bridged the gap between the ProActive Study and her transplant population by extending protocolized use. In this episode, we discuss her:
    -experience expanding protocolized use on non-study patients
    -patients belief in the value of serial Prospera testing through the right education
    -message to colleagues looking to begin using cfDNA/p>